# Drugs Made In America Acquisition Corp. (DMAA)

**Exchange:** NASDAQ  
**Sector:** Financial Services  
**Price:** $10.61 (+0.05%)

> Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) established in 2024 and headquartered in Fort Lauderdale, Florida. The company’s primary purpose is to facilitate a merger, share exchange, asset acquisition, or similar business combination with one or more businesses in the U.S. pharmaceutical sector. Emphasizing the importance of domestic pharmaceutical manufacturing, the firm actively seeks to identify and acquire revenue-generating businesses that can serve as the foundation for an "end-to-end" platform focused on producing drugs within the United States. By doing so, it aims to contribute to job creation, strengthen national security, and ensure a reliable domestic supply of affordable, high-quality medications. The company is guided by an experienced management and advisory team, including prominent industry leaders, leveraging deep sector relationships and expertise to achieve its objectives. In the broader financial market, Drugs Made In America Acquisition Corp. represents the growing trend of SPACs targeting healthcare innovation and supply chain resilience, positioning itself as a strategic player in the future landscape of U.S. pharmaceutical manufacturing.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/DMAA)